OSSIX™ Bone 0.500 ccRecalls & reported problems
Datum Dental Ltd · OSSIX™ BONE is a biodegradable, osteoconductive, and biocompatible bone grafting material intended for guided tissue and bone regeneration. The OSSIX™ BONE matrix is composed of 80% synthetic crystalline non-sintered hydroxylapatite and 20% collagen, which is derived from veterinary certified pigs and is purified and cross-linked. · Class 2 · Implant
- Adverse event reports
- 2
- Deaths reported
- 0
- Injuries reported
- 2
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 07290015477253), received between Oct 11, 2022 and Oct 22, 2025 — classified as 2 injuries.
The most frequently reported specific device problem is “Failure to Osseointegrate” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Reports received per month
Most reported problems
Device problems
- Failure to Osseointegrate1
- Use of Device Problem1
Patient problems
- Difficulty Chewing1
- Insufficient Information1
- Osteomyelitis1
- Swelling/ Edema1
Recent adverse event reports
The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.
InjuryOct 22, 2025Failure to Osseointegrate; Failure to Osseointegrate
IN THIS EVENT IT IS REPORTED THAT OSSIX BONE 5*10*10 (0.5 CC) WAS USED IN TREATMENT. CUSTOMER REPORTS THAT WHEN THE AREA WAS REOPENED AFTER 6 MONTHS, NO BONE FORMED. THE PRODUCT REMAINS SPONGY/RUBBERY. THIS IS A OSSEOINTEGRATION ISSUE.
Patient problems: Insufficient Information
MAUDE report 23356382 ↗InjuryOct 11, 2022Use of Device Problem; Use of Device Problem
A DOCTOR REPORTED THAT THEY REMOVED TEETH 15-16 AND PLACED OSSIX BONE IN A SOCKET PRESERVATION PROCEDURE. THE DOCTOR DID NOT HYDRATE THE MATERIAL PRIOR TO PLACEMENT. THE PATIENT INDICATED 3 DAYS POST PROCEDURE THAT THEY DEVELOPED SWELLING AND WERE PRESCRIBED AMOXICILLIN. AT THE ONE-WEEK POST-OP VISIT, THE DOCTOR NOTED SLIGHT SWELLING AND PRESCRIBED THE PATIENT MEDROL DOSE PACK. LATER THE PATIENT CALLED TO INDICATE THEIR JAW FELT STIFF AND THEY WERE PRESCRIBED CYCLOBENZAPRINE MUSCLE RELAXANT. THE PATIENT LATER DEVELOPED SWELLING AT THE ANGLE OF HER MANDIBLE AND WAS INSTRUCTED TO GO TO THE EMERGENCY ROOM BY TREATING DOCTOR. THE TREATING DOCTOR AT THE ER DIAGNOSED THE PATIENT WITH OSTEOMYELITIS AND THEY WERE REFERRED TO AN INFECTIOUS DISEASE SPECIALIST WHO PLACED THE PATIENT ON IV ANTIBIOTICS THERAPY FOR 2 DAYS. THE PATIENT RETURNED TO THE REPORTING OFFICE APPROXIMATELY ONE MONTH POST PROCEDURE TO BE SEEN BY THE MAXILLOFACIAL SURGEON AND THEY NOTED THERE WERE NO SIGNS OF OSTEOMYELITIS. THE WOUND WAS REOPENED AND THE OFFICE PERFORMED AN IRRIGATION AND DEBRIDEMENT. THE TREATING OFFICE INDICATED, THE PATIENT HAS NOT FOLLOWED UP WITH THE INFECTIOUS DISEASE SPECIALIST AND IS NOT TAKING THE
Patient problems: Difficulty Chewing; Osteomyelitis; Swelling/ Edema
MAUDE report 15577264 ↗
Other Bone Grafting Material, Animal Source devices
- RegenerOss Resorbable Xenograft ROXR40Collagen Matrix, Inc. · Bone Grafting Material, Animal Source1 recall1 report
- NuOss 5091003Ace Surgical Supply CO., Inc. · BONE GRAFTING MATERIAL, ANIMAL SOURCE1 recall0 reports
- Gibson Healthcare® Bone Graft Plug 5824-413Collagen Matrix, Inc. · Bone Grafting Material, Animal Source6 reports
- OSSIX™ Bone 0.250 ccDatum Dental Ltd · Bone Grafting Material, Animal Source5 reports
- NuOss 5091004Ace Surgical Supply CO., Inc. · BONE GRAFTING MATERIAL, ANIMAL SOURCE5 reports
- PreservaRidge™ Plug PRPREGCollagen Matrix, Inc. · Bone Grafting Material, Animal Source3 reports
- NuOss 5099002Ace Surgical Supply CO., Inc. · BONE GRAFTING MATERIAL, ANIMAL SOURCE3 reports
- NuOss 5099100Ace Surgical Supply CO., Inc. · BONE GRAFTING MATERIAL, ANIMAL SOURCE3 reports
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.